Unicycive Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the Annual Meeting of Stockholders held by Unicycive Therapeutics, Inc. on June 20, 2024. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Los Altos, California. The record date for the meeting was April 25, 2024.
Key Financial Metrics
This filing is a current report regarding corporate governance and stockholder votes. It does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes and Voting Results
Approximately 78% of the total voting power (35,912,732 votes) was represented at the meeting. The following matters were submitted to a vote and approved:
- Proposal 1 (Election of Directors): All four nominees (Dr. Shalabh Gupta, Dr. Sandeep Laumas, Dr. Gaurav Aggarwal, and Dr. Saraswati Kenkare-Mitra) were elected to serve until the 2025 Annual Meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of Grassi & Co. CPAs, P.C. as the independent registered public accounting firm for the fiscal year ended December 31, 2024.
- Proposal 3 (Nasdaq 20% Issuance): The proposal to increase the number of shares of common stock that may be issued under the Company's equity incentive plans was approved.
- Proposal 4 (Authorized Share Increase): The proposal to increase the number of authorized shares of common stock was approved.
- Proposal 5 (Equity Incentive Plan Amendment): The second amendment and restatement of the 2021 Omnibus Equity Incentive Plan was approved.
Guidance, Outlook, and Risks
The filing does not contain management commentary on financial guidance, future outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting results.
Key Facts for Investor Verification
- Verify the specific terms of the approved "Nasdaq 20% Issuance Proposal" and "Authorized Share Increase Proposal" in the Definitive Proxy Statement filed on April 26, 2024, to understand potential dilution impacts.
- Review the detailed vote counts for the election of directors, noting that Dr. Sandeep Laumas and Dr. Saraswati Kenkare-Mitra received a higher percentage of "Withhold" votes compared to the other nominees.
- Confirm the details of the amended 2021 Omnibus Equity Incentive Plan to assess future equity compensation costs.
- Check subsequent filings for the Company's financial performance, as this 8-K contains no financial data.